



Teikoku Pharma USA, Inc.



Commitment. Discovery. **Partnership.**
www.teikokupharma.com

Teikoku Seiyaku Co., Ltd.
Higashi-Kagawa, Japan



London, UK
Teikoku Pharma UK, Ltd.

Higashi-Kagawa, Japan
Teikoku Kampo Seiyaku Co., Ltd.
Teikoku Pharmacare Co., Ltd.

Osaka, Japan
Fuso Chemical
Industry Co., Ltd.

Saitama, Japan
Teikoku Medix Co., Ltd.


San Jose, United States
Teikoku Pharma USA, Inc.

Qingdao, China
Fuso Teiyaku
Co., Ltd



A Heritage of Discovery

Teikoku Pharma USA is a wholly owned subsidiary of Teikoku Seiyaku Co. , Ltd. of Japan and one of the world's leading experts in transdermal drug delivery systems (TDS).



Through our efforts to chart new territory in prescription, OTC, and medical device markets around the world, we transform ideas into products that will meet consumers' needs.

Our parent company, which was established in 1848, pioneered the development of some of the earliest TDS technologies. While the challenges facing pharmaceutical companies today are far different from what they were when Teikoku Seiyaku opened its doors over 150 years ago, the keys to success in the pharmaceutical business are not: it still takes a willingness to explore alternative solutions, the talent to develop new technologies, and the ability to see potential where others can't. These characteristics are the hallmarks of Teikoku Pharma USA.

We work to expand transdermal drug delivery opportunities through the in-licensing of new products and out-licensing of our technology. Whether by applying our TDS technologies to existing products or co-developing new formulations, we help pharmaceutical companies extend patent protections, diversify their product lines, provide better delivery mechanisms, and promote brand loyalty.

"We currently manufacture
some **200 patch**
and **ointment products**".



Products

Pain Management & Beyond

A commitment to pain management and improved quality of life is what drives the product development efforts of Teikoku Seiyaku and its subsidiaries around the world. We currently manufacture some 200 patch and ointment products.

Lidoderm, Teikoku Pharma USA's first prescription product launched in the United States, is a prescription patch designed to relieve the pain of post-herpetic neuralgia (a side effect of shingles). Launched in 1999 in collaboration with Endo Pharmaceuticals, Lidoderm was the first hydrogel patch to be approved by the FDA in the United States, and by 2003 was one of Endo Pharmaceutical's best-selling products.

Our product development efforts have expanded into new technologies, including oral jellies. Easily swallowed and less bitter than their liquid counterparts, oral jellies can improve compliance among elderly patients and children, can be easily administered, and allow for precise dosage control.

We are also working with several cosmetic companies to develop TDS-based health and beauty products such as face masks, anti-wrinkle patches, skin whitening products, and cuticle softeners.

The Teikoku Group distributes to over 40 countries worldwide. The Flector series, containing 1.3% Diclofenac, is marketed throughout Europe and Latin America by our partner Institut Biochimique S. A. (IBSA). Flector is an analgesic and anti-inflammatory patch for minor sports injuries.




Technology

Creating Platforms for New Opportunities

Most drugs today are taken orally. While this delivery mechanism is effective and relatively noninvasive, TDS technologies provide even greater benefits to the end user. They offer targeted drug delivery and absorption, avoid first-pass metabolism, present a quick and easy interruption option if an adverse reaction occurs, and improve patient compliance thanks to their ease of use.

Teikoku Seiyaku created one of the world's first analgesic plasters over 60 years ago and has long been a leader in the search for effective and non-invasive drug delivery systems. Today, our comprehensive product line includes hydrogel patches, anhydrous patches (tapes), creams and ointments, unit-dose liquids, and unit-dose jellies.

All of our products can provide powerful alternative delivery mechanisms for existing drug formulations, or platforms for new formulations for everything from pain management to cosmetic care.



Drug-in-adhesive Transdermal Drug Delivery Systems allow for uniform rates of drug delivery because the adhesive is designed for the specific compound the patch carries. This type of product is more comfortable than reservoir patches because the drug is incorporated directly into the adhesive.



Transdermal Drug Delivery Systems (TDS)


Transdermal drug delivery involves the delivery of drugs through the skin.

Topical drug delivery systems apply formulations to the skin with the goal of localized application and minimal systemic circulation. With topical drug delivery systems, the active does not enter the bloodstream.

Systemic drug delivery systems introduce drugs through the skin to treat areas that are remote from the application site. They offer many of the benefits of intravenous administration without the invasiveness of syringes or pumps. Unlike topical drug delivery systems, they do introduce the active to the bloodstream.

TDS Offer the Best of Oral and IV Drug Delivery

	IV	Oral	TDS
Reduced first-pass effects	✓		✓
Constant drug levels		✓	✓
Self-administration		✓	✓
Unrestricted patient activity		✓	✓
Non-invasive	✓		✓



Research & Development

Our search for solutions never ends

The members of Teikoku Pharma USA's research and development team focus on developing new formulations and determining whether prospective partners' products are compatible with our TDS technologies.

Our product development efforts have expanded into new therapeutic areas, including wound care and the treatment of respiratory diseases and dermatological conditions. While we focus primarily on prescription products, we also apply our TDS technologies to the OTC and cosmetic markets.

To stay apprised of drug delivery research and development activities in different markets around the world, we work closely with leading researchers in our field and remain in constant contact with Teikoku Seiyaku's large R&D staff in Japan. Reciprocal information and idea sharing among members of this borderless team have helped us acquire new technologies, enhance existing solutions, and expand our collective expertise.

In our search for new and improved TDS technologies, We also partner with other companies that specialize in this area, pooling our respective resources and knowledge to explore emerging technologies and their potential uses.



Production & Distribution

Capacity and Flexibility

The Best of Both Worlds

Teikoku Pharma USA is exceptionally skilled at developing, formulating, and adapting products for large-scale manufacturing. While large in size, we are nimble in our operations. This allows us to respond quickly and effectively to our customers' changing needs, both during the development phase and after launch.

Our research and development labs are linked to our production facilities through integrated technologies so that we can transform the first glimmer of an idea into a marketable product in months rather than years.

Capacity is second only to quality when it comes to the characteristics you look for in a pharmaceutical manufacturer. We leverage the resources of our parent company, Teikoku Seiyaku, by producing all of our products at their facility in Japan. Their hydrogel patch production facility, the largest in the world, is capable of producing four billion patches annually. This site sets the standard in the industry for quality and safety.

Teikoku Seiyaku's efforts to expand into markets in Europe, Asia, and South America have been met with good results. Our medicated patches and plasters are currently distributed in more than 40 countries.



Partnership

We did not become such a strong player in the TDS marketplace simply by manufacturing a lot of patches. We earned this distinction by taking the meaning of partnership to a new level.

At Teikoku Pharma USA, we believe that our approach to partnership is a key contributor to our success — and to the success of our partners. To every one of our relationships we bring:

- The **expertise** to develop and manufacture superior dermal drug delivery-based technologies and products;
- The **integrity** to comply with established standards of conduct, deal with our partners openly and honestly, and stand by the quality of our products; and
- The **flexibility** to adapt high-volume production to the changing needs of the marketplace.

The challenges facing pharmaceutical companies today are far different from what they were when Teikoku Seiyaku opened its doors in 1848. What haven't changed over the last 150 years are the keys to success in the pharmaceutical business: Creative thinking. A willingness to explore alternative solutions. The talent to develop new technologies. And the ability to see potential where others can't.

At Teikoku Pharma USA, we'll continue to take the lead and let others follow.



A Representative List of Our Partners:

- Altea Therapeutics
- Beiersdorf
- Chong Kun Dang
- Endo Pharmaceuticals
- Grünenthal
- Institut Biochimique S.A.
- Kakken
- LAB Pharma
- Lion
- Sanofi-Aventis
- Shiseido
- SK Chemicals
- Taisho

**To learn more about developing a partnership
with Teikoku Pharma USA, please contact our
Business Development team at (408) 501-1800**

We look forward to working with you



Teikoku Pharma USA

Teikoku Pharma USA

1718 Ringwood Avenue
San Jose, California 95131-1711

Phone: (408) 501-1800

Website: www.teikokupharma.com

Headquarters

Teikoku Seiyaku Co., Ltd.

567 Sanbonmatsu Higashi-Kagawa,
Kagawa 769-2695 Japan

Phone: +81-879-25-2221

Website: www.teikoku.co.jp